Page 122 - Read Online

Best et al. Hepatoma Res 2020;6:62 I http://dx.doi.org/10.20517/2394-5079.2020.56 Page 13 of 13

diagnosis. Int J Mol Sci 2018;19.
74. Zhang C, Wang P, Li Y, Huang C, Ni W, et al. Role of MicroRNAs in the development of hepatocellular carcinoma in nonalcoholic fatty
liver disease. Anat Rec (Hoboken) 2019;302:193-200.
75. Kutlu O, Kaleli HN, Ozer E. Molecular pathogenesis of nonalcoholic steatohepatitis- (NASH-) related hepatocellular carcinoma. Can J
Gastroenterol Hepatol 2018;2018:8543763.
76. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014;59:328-39.
77. Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, et al. Gut(-)Liver Axis: how do gut bacteria influence the liver? Med Sci
(Basel) 2018;6.
78. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology
2014;146:1489-99.
79. Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab 2016;5:782-94.
80. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. An obesity-associated gut microbiome with increased capacity for
energy harvest. Nature 2006;444:1027-31.
81. Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol
2016;13:508-16.
82. Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in
mice via beneficial regulation of gut microbiota. Sci Rep 2017;7:1529.
83. de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and
future. Gut Microbes 2017;8:253-67.
84. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and
TLR4. Cancer Cell 2012;21:504-16.
85. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through
senescence secretome. Nature 2013;499:97-101.
86. Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, et al. Hepatocellular carcinoma is associated with gut microbiota profile and
inflammation in nonalcoholic fatty liver disease. Hepatology 2019;69:107-20.
87. Schonewille M, de Boer JF, Groen AK. Bile salts in control of lipid metabolism. Curr Opin Lipidol 2016;27:295-301.
88. Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS
One 2016;11:e0151829.
89. Neuschwander-Tetri BA, Van Natta ML, Tonascia J, Brunt EM, Kleiner DE. Trials of obeticholic acid for non-alcoholic steatohepatitis -
Authors’ reply. Lancet 2015;386:28-9.
90. Liu Q, Li F, Zhuang Y, Xu J, Wang J, et al. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related
hepatocellular carcinoma. Gut Pathog 2019;11:1.
91. Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R. Altered microbiota diversity and bile acid signaling in cirrhotic and
noncirrhotic NASH-HCC. Clin Transl Gastroenterol 2020;11:e00131.
92. Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, et al. Suppressed hepatic bile acid signalling despite elevated production of
primary and secondary bile acids in NAFLD. Gut 2018;67:1881-91.
93. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, et al. Free fatty acids repress small heterodimer partner (SHP) activation and
adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013;57:1394-
406.
94. Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver
disease. Nat Commun 2019;10:1406.
95. Nowak A, Paliwoda A, Blasiak J. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium
strains: a review of mechanisms and therapeutic perspectives. Crit Rev Food Sci Nutr 2019;59:3456-67.
96. Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver
diseases. Hepatol Res 2020;50:817-30.
97. Pei Y, Zhang T, Renault V, Zhang X. An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin
(Shanghai) 2009;41:1-15.
98. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, et al. Factors that affect efficacy of ultrasound surveillance for early stage
hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1927-33.e2.
99. Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist
in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res 2009;42:958-62.
100. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic
steatohepatitis. J Gastroenterol 2009;44:1190-4.